Suicide attempts are increasing by people who are using two drugs that are often prescribed as a substitute for opioid therapy for chronic pain.
Researchers found that patients who use gabapentin, an anti-epileptic drug used to treat nerve pain, and baclofen, a muscle relaxant, were increasingly pondering suicide.
Suicide rates have jumped in the U.S. Between 1999 and 2016, suicide rates are up by nearly one-third.
And of course, even though there are no data yet reported, suicide rates with people with chronic pain are known to have been increasing given the restrictions on opioid prescribing that has occurred since the CDC Guideline was published in 2016.
The Marfan Foundation has awarded a team of New York Institute of Technology researchers, led by Joanne Donoghue, Ph.D., associate professor and director of clinical research at NYITCOM, funding to investigate the impact of Hypermobile EDS on the gastrointestinal system
One out of 5,000 individuals worldwide is affected by EDS. It is a rare group of hypermobility spectrum disorders (conditions where joints easily move beyond the normal range of motion) that affect the connective tissues supporting the skin, bones, blood vessels, and other organs. While healthy patients have connective tissue made of sturdy collagen, which allows the tissue to be stretched to its limit and then safely returned to its normal position, patients with EDS have fragile connective tissue with insufficient or faulty collagen. EDS can be life threating if blood vessels or heart tissue are affected.
Minnesota Marijuana Adds Chronic Pain Designation
Chronic pain patients in Minnesota will be able use medical cannabis legally next year. The Minnesota Department of Health announce it is adding chronic pain and age-related macular degeneration to qualify under the state’s medical cannabis programs.
The program’s two medical cannabis manufacturers will double the number of patient cannabis treatment centers in accordance with legislation passed during the 2019 Minnesota Legislative Session. These new sites will mean greater access to cannabis treatment centers.